Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2Unknown 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Sarcoma, Kaposi 4Leukemia, Lymphocytic, Chronic, B-Cell 2Epstein-Barr Virus Infections 2Cytomegalovirus Infections 2Acquired Immunodeficiency Syndrome 2Sarcoma 1Multi-centric Castleman's Disease 1Lymphoproliferative Disorders 1Lymphoma 1Leukemia 1Immune Reconstitution Inflammatory Syndrome 1Herpes Simplex 1Glioblastoma 1Fatigue Syndrome, Chronic 1Fatigue 1Castleman Disease 1

Interventions

Rituximab 4Valganciclovir 2Valacyclovir 2Carboplatin 2Acyclovir 2valomaciclovir 1threonic acid 1otelixizumab 1cc-486 1Zidovudine 1Vincristine 1Vaccines 1Tomography, X-Ray Computed 1Prednisone 1Polymerase Chain Reaction 1Methotrexate 1Matrix-M 1Magnesium Sulfate 1MVA vaccine 1Leucovorin 1Kidney Transplantation 1Interferons 1In Situ Hybridization 1Immunohistochemistry 1Granulocyte Colony-Stimulating Factor 1Gene-Eden-VIR 1Gastrectomy 1Flow Cytometry 1Filgrastim 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Epstein-Barr Virus Infections × Valganciclovir × Clear all
NCT00478465 2022-05-27

Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)

Stanford University

Phase 1/2 Completed
30 enrolled

Fatigue, Herpes Simplex, Fatigue Syndrome, Chronic, Epstein-Barr Virus Infections

NCT01972035 2022-04-12

ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation

University of Minnesota

Phase 2 Completed
137 enrolled 8 charts

Cytomegalovirus Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡